Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. more
Time Frame | MEIP | Sector | S&P500 |
---|---|---|---|
1-Week Return | 5.77% | 0.31% | -1.26% |
1-Month Return | 6.59% | 0.6% | -4.16% |
3-Month Return | 3% | -9.44% | -0.46% |
6-Month Return | -3.17% | -5.15% | 3.58% |
1-Year Return | -46.39% | 0.33% | 22.47% |
3-Year Return | -94.48% | 4.53% | 25.13% |
5-Year Return | -93.75% | 35.98% | 77.7% |
10-Year Return | -96.57% | 100.72% | 190.12% |
Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 28.91M | 25.54M | 40.70M | 48.82M | 65.30M | [{"date":"2020-06-30","value":44.28,"profit":true},{"date":"2021-06-30","value":39.11,"profit":true},{"date":"2022-06-30","value":62.33,"profit":true},{"date":"2023-06-30","value":74.76,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Cost of Revenue | 2.67M | 1.41M | 1.24M | 1.81M | 383.00K | [{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":52.71,"profit":true},{"date":"2022-06-30","value":46.24,"profit":true},{"date":"2023-06-30","value":67.95,"profit":true},{"date":"2024-06-30","value":14.34,"profit":true}] |
Gross Profit | 26.24M | 24.13M | 39.46M | 47.00M | 64.91M | [{"date":"2020-06-30","value":40.43,"profit":true},{"date":"2021-06-30","value":37.17,"profit":true},{"date":"2022-06-30","value":60.79,"profit":true},{"date":"2023-06-30","value":72.41,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Gross Margin | 90.76% | 94.49% | 96.97% | 96.28% | 99.41% | [{"date":"2020-06-30","value":91.3,"profit":true},{"date":"2021-06-30","value":95.04,"profit":true},{"date":"2022-06-30","value":97.54,"profit":true},{"date":"2023-06-30","value":96.85,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Operating Expenses | 50.78M | 93.81M | 116.18M | 85.58M | 50.76M | [{"date":"2020-06-30","value":43.71,"profit":true},{"date":"2021-06-30","value":80.75,"profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":73.66,"profit":true},{"date":"2024-06-30","value":43.69,"profit":true}] |
Operating Income | (24.54M) | (69.69M) | (75.48M) | (36.76M) | 14.54M | [{"date":"2020-06-30","value":-168.75,"profit":false},{"date":"2021-06-30","value":-479.2,"profit":false},{"date":"2022-06-30","value":-519.08,"profit":false},{"date":"2023-06-30","value":-252.81,"profit":false},{"date":"2024-06-30","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (20.08M) | 19.63M | 21.31M | 8.27M | 6.51M | [{"date":"2020-06-30","value":-94.21,"profit":false},{"date":"2021-06-30","value":92.09,"profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":38.81,"profit":true},{"date":"2024-06-30","value":30.56,"profit":true}] |
Pre-Tax Income | (46.02M) | (50.57M) | (54.45M) | (31.84M) | 17.78M | [{"date":"2020-06-30","value":-258.83,"profit":false},{"date":"2021-06-30","value":-284.44,"profit":false},{"date":"2022-06-30","value":-306.3,"profit":false},{"date":"2023-06-30","value":-179.09,"profit":false},{"date":"2024-06-30","value":100,"profit":true}] |
Income Taxes | 1.00K | 8.00K | 284.00K | (4.95M) | 7.62M | [{"date":"2020-06-30","value":0.01,"profit":true},{"date":"2021-06-30","value":0.1,"profit":true},{"date":"2022-06-30","value":3.73,"profit":true},{"date":"2023-06-30","value":-64.92,"profit":false},{"date":"2024-06-30","value":100,"profit":true}] |
Income After Taxes | (46.02M) | (50.58M) | (54.74M) | (26.89M) | 10.16M | [{"date":"2020-06-30","value":-453.09,"profit":false},{"date":"2021-06-30","value":-497.98,"profit":false},{"date":"2022-06-30","value":-538.97,"profit":false},{"date":"2023-06-30","value":-264.77,"profit":false},{"date":"2024-06-30","value":100,"profit":true}] |
Income From Continuous Operations | (46.02M) | (50.58M) | (54.45M) | (31.84M) | 17.78M | [{"date":"2020-06-30","value":-258.84,"profit":false},{"date":"2021-06-30","value":-284.48,"profit":false},{"date":"2022-06-30","value":-306.3,"profit":false},{"date":"2023-06-30","value":-179.09,"profit":false},{"date":"2024-06-30","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Net Income | (46.02M) | (41.31M) | (54.45M) | (31.84M) | 17.78M | [{"date":"2020-06-30","value":-258.84,"profit":false},{"date":"2021-06-30","value":-232.37,"profit":false},{"date":"2022-06-30","value":-306.28,"profit":false},{"date":"2023-06-30","value":-179.1,"profit":false},{"date":"2024-06-30","value":100,"profit":true}] |
EPS (Diluted) | (0.53) | (0.45) | (0.35) | (3.87) | 2.67 | [{"date":"2020-06-30","value":-19.85,"profit":false},{"date":"2021-06-30","value":-16.85,"profit":false},{"date":"2022-06-30","value":-13.11,"profit":false},{"date":"2023-06-30","value":-144.94,"profit":false},{"date":"2024-06-30","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
MEIP | |
---|---|
Cash Ratio | 9.37 |
Current Ratio | 9.66 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MEIP | |
---|---|
ROA (LTM) | 20.04% |
ROE (LTM) | 61.68% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MEIP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MEIP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.28 |
P/B | 0.73 |
Price/FCF | NM |
EV/R | 1.39 |
EV/Ebitda | NM |
PEG | 20.60 |
MEI Pharma Inc (MEIP) share price today is $2.75
Yes, Indians can buy shares of MEI Pharma Inc (MEIP) on Vested. To buy MEI Pharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MEIP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of MEI Pharma Inc (MEIP) via the Vested app. You can start investing in MEI Pharma Inc (MEIP) with a minimum investment of $1.
You can invest in shares of MEI Pharma Inc (MEIP) via Vested in three simple steps:
The 52-week high price of MEI Pharma Inc (MEIP) is $5.06. The 52-week low price of MEI Pharma Inc (MEIP) is $2.3.
The price-to-earnings (P/E) ratio of MEI Pharma Inc (MEIP) is
The price-to-book (P/B) ratio of MEI Pharma Inc (MEIP) is 0.73
The dividend yield of MEI Pharma Inc (MEIP) is 0.00%
The market capitalization of MEI Pharma Inc (MEIP) is $18.32M
The stock symbol (or ticker) of MEI Pharma Inc is MEIP